Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

34results about How to "High recovery rate of activity" patented technology

Method for preparing freeze-dried human blood coagulation factor VIII

The invention discloses a method for preparing a freeze-dried human blood coagulation factor VIII. The method comprises the following process of: dissolving by taking water for injection, comprising 3-10 IU (International Unit)/ml of heparin, as a heparin sodium solution and cryoprecipitating; performing PEG (Polyethylene Glycol) precipitation and taking supernatant; performing centrifugal filtration; performing S/D (Solvent/Detergent) inactivation at the temperature of 24-26 DEG C; performing DEAE (Diethylaminoethyl) Sepharose Fast Flow chromatographic column balance, adsorption, washing andelution; performing molecular membrane ultrafiltration; preparing, removing bacteria, sub-packaging, freeze-drying and capping; and dry-heating at the temperature of 99.5-100.5 DEG C and inactivating. In the invention, the process method of combining the PEG precipitation and an ion exchange chromatography technology is adopted; the method is easy and convenient to operate; the F VIII active recovery rate is increased; miscellaneous proteins can be removed on a large scale; the product yield reaches over 60 percent; and the specific activity of the product reaches 5 IU/mg and is obviously greater than a value which is not less than 1 IU/mg stipulated in the pharmacopeia. Meanwhile, the PEG residue is 0.08g/L which is obviously less than the value which is less than or equal to 0.5 IU/mg stipulated in the pharmacopeia, so that Al<3+> residues in the final preparation of an Al(OH)3 gel method are avoided; the product has high purity and high safety; and the quality of the final product is obviously improved.
Owner:NANYUE BIOPHARMING

Method for preparing freeze-dried human blood coagulation factor VIII

The invention discloses a method for preparing a freeze-dried human blood coagulation factor VIII. The method comprises the following process of: dissolving by taking water for injection, comprising 3-10 IU (International Unit) / ml of heparin, as a heparin sodium solution and cryoprecipitating; performing PEG (Polyethylene Glycol) precipitation and taking supernatant; performing centrifugal filtration; performing S / D (Solvent / Detergent) inactivation at the temperature of 24-26 DEG C; performing DEAE (Diethylaminoethyl) Sepharose Fast Flow chromatographic column balance, adsorption, washing andelution; performing molecular membrane ultrafiltration; preparing, removing bacteria, sub-packaging, freeze-drying and capping; and dry-heating at the temperature of 99.5-100.5 DEG C and inactivating. In the invention, the process method of combining the PEG precipitation and an ion exchange chromatography technology is adopted; the method is easy and convenient to operate; the F VIII active recovery rate is increased; miscellaneous proteins can be removed on a large scale; the product yield reaches over 60 percent; and the specific activity of the product reaches 5 IU / mg and is obviously greater than a value which is not less than 1 IU / mg stipulated in the pharmacopeia. Meanwhile, the PEG residue is 0.08g / L which is obviously less than the value which is less than or equal to 0.5 IU / mg stipulated in the pharmacopeia, so that Al<3+> residues in the final preparation of an Al(OH)3 gel method are avoided; the product has high purity and high safety; and the quality of the final product is obviously improved.
Owner:NANYUE BIOPHARMING

Process for preparing human prothrombin complex concentrate by adopting flow adsorption method

The invention discloses a process for preparing a human prothrombin complex concentrate by adopting a flow adsorption method. The process is characterized in that a plurality of cylindrical containerswith stirrers are connected in series to form a natural flowing way; gels which are balanced in advance are placed in the various containers; a certain batch of to-be-processed blood plasma is storedabove the first container; the gels are injected quantitatively firstly in the first container, then the gels are stirred and adsorbed for a unit time, and the adsorbed blood plasma is discharged into the second container at a certain flow speed; simultaneously, other to-be-processed blood plasma flows into a first adsorption tank at the same flow speed, so that dynamic balance of the blood plasma quantity in the first container is kept, and at this time, adsorption and separation of the blood plasma in the first container are carried out simultaneously; by analogy, after the all blood plasmapasses through, outlets of the various containers are closed, and washing and elution on the gels are carried out. The blood plasma quantity is not limited by the volume of the containers, the process is easily controlled, an FIX activety recycling ratio is higher, and the risks of leakage of the gels and crossed pollution are avoided.
Owner:华润博雅生物制药集团股份有限公司

A temperature-controlled phase change material microcapsule carrier immobilized enzyme and its preparation method

The invention discloses a temperature-regulated phase material microcapsule carrier immobilized enzyme and a preparation method for the same, and relates to the technical field of biology. The preparation method comprises the following steps: preparing a microcapsule carrier obtained by cladding an organic phase change material with a crystalline titanium dioxide / magnetic particle composite material, performing carboxylation modification on the microcapsule carrier, and implementing enzyme immobilization by adopting a chemical coupling method, so as to finally obtain the temperature-regulated phase material microcapsule carrier immobilized enzyme. According to the temperature-regulated phase material microcapsule carrier immobilized enzyme and the preparation method for the same, heat can be stored and released by the microcapsule carrier of the immobilized enzyme through a phase change material capsule core, so that micro-environmental temperature around the carrier can be regulated, the temperature application range of enzymatic reaction can be widened, and the heat stability, the storage stability and the cycling stability of the immobilized enzyme can be enhanced. In addition, the temperature-regulated phase change material microcapsule carrier can be used for immobilizing different types of enzymes, and is wide in application range.
Owner:BEIJING UNIV OF CHEM TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products